The drug, in combination with chemotherapy, helped patients with advanced colorectal cancer live significantly longer.
Details will be released at an upcoming medical meeting. Regeneron is developing the product with drug giant Sanofi-Aventis (NYSE:SNY).
The companies said they hope to file for U.S.
Regeneron Pharmaceuticals (NASDAQ:REGN) soared over 40% at one point Wednesday afternoon, after the company reported positive results from a Phase III study for its drug Zaltrap.